The 4000th eye tumour patient treated with protons at HZB

Overview: Number of patients treated with prontons at HZB from 1998 to 2020.  

Overview: Number of patients treated with prontons at HZB from 1998 to 2020.   © HZB/S. Kodalle

On 19 February 2021, the 4000th eye tumour patient received irradiation with protons, performed by a joint team from Helmholtz-Zentrum Berlin (HZB) and Charité - Universitätsmedizin Berlin. The number of patients treated in 2020 remained at the previous year's level despite the more difficult corona conditions. The treatment in Berlin-Wannsee is only available for uveal melanomas of the eye. The proton accelerator at HZB is the only therapy site for this disease in Germany.

For more than 20 years, Charité - Universitätsmedizin Berlin and Helmholtz-Zentrum Berlin (HZB) have jointly offered irradiation of eye tumours with protons. For this purpose, the HZB operates a proton accelerator, while the medical care of patients is provided by the Charité.

"We congratulate the joint team on this great success and thank them for doing everything they could under the difficult pandemic conditions to maintain the operation of the life-saving eye tumour therapy," says Prof. Bernd Rech, spokesman for the scientific management of HZB. 

500 to 600 people contract malignant uveal melanoma in Germany every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be preserved to a satisfactory degree. Radiation with protons is a particularly effective method: the energy of the proton beam can be adjusted in such a way that practically only the tumour receives the radiation, while the surrounding healthy tissue is spared.

sz

  • Copy link

You might also be interested in

  • Hydrogen: Breakthrough in alkaline membrane electrolysers
    Science Highlight
    28.10.2024
    Hydrogen: Breakthrough in alkaline membrane electrolysers
    A team from the Technical University of Berlin, HZB, IMTEK (University of Freiburg) and Siemens Energy has developed a highly efficient alkaline membrane electrolyser that approaches the performance of established PEM electrolysers. What makes this achievement remarkable is the use of inexpensive nickel compounds for the anode catalyst, replacing costly and rare iridium. At BESSY II, the team was able to elucidate the catalytic processes in detail using operando measurements, and a theory team (USA, Singapore) provided a consistent molecular description. In Freiburg, prototype cells were built using a new coating process and tested in operation. The results have been published in the prestigious journal Nature Catalysis.
  • Perovskite solar cells: TEAM PV develops reproducibility and comparability
    News
    22.10.2024
    Perovskite solar cells: TEAM PV develops reproducibility and comparability
    Ten teams at Helmholtz-Zentrum Berlin are building a long-term international alliance to converge practices and develop reproducibility and comparability in perovskite materials. The TEAM PV project is funded by the Federal Ministry of Education and Research (BMBF), Germany.
  • HZB patent for semiconductor characterisation goes into serial production
    News
    10.10.2024
    HZB patent for semiconductor characterisation goes into serial production
    An HZB team has developed together with Freiberg Instruments an innovative monochromator that is now being produced and marketed. The device makes it possible to quickly and continuously measure the optoelectronic properties of semiconductor materials with high precision over a broad spectral range from the near infrared to the deep ultraviolet. Stray light is efficiently suppressed. This innovation is of interest for the development of new materials and can also be used to better control industrial processes.